Clinical Trial

A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 21, 2024 (before its estimated March 22, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy and safety of cardunolizumab in combination with/without chemotherapy ± bevacizumab for recurrent or metastatic vulvar and vaginal cancers that are not amenable to radical treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-04.
Status change: Not Yet Recruiting → Recruiting 2024-11-20
Trial Details
NCT Number NCT06292689
Lead Sponsor Zhejiang Cancer Hospital
Collaborators: Akeso, Innovent Biologics, Inc.
Conditions Vulvar and Vaginal Cancer
Enrollment 40 participants
Start Date 2024-03-22
Primary Completion 2026-03-22 (estimated)
Study Completion 2027-03-22 (estimated)
Updated on ClinicalTrials.gov 2024-11-21